How a patient-led advocacy organization supports the road to diagnosis and treatment of creatine transporter deficiency

Abstract: The current era of drug development has evolved significantly. Patient advocacy organizations are moving beyond simply supporting community members and are taking the reins to improve the speed of diagnoses, initiate therapeutic discoveries, and lay the groundwork to ensure successful clinical trials. The Association for Creatine Deficiencies (ACD) is an international parent-led patient advocacy organization focused on the three ultra-rare neurodevelopmental monogenic disorders resulting in Cerebral Creatine Deficiency Syndromes (CCDS). These include X-linked creatine transporter deficiency (CTD), guanidinoacetate methyltransferase (GAMT) deficiency, and l-arginine:glycine amidinotransferase (AGAT) deficiency. While each is rare in its own right, the unified CCDS community is effectively advancing the field of CCDS with each disorder benefiting from progress made in the other two disease areas. ACD collaborators include caregivers, academic researchers, clinicians, industry partners, and policymakers. Since its founding in 2012, the organization has evolved and achieved significant milestones. These include advancements in disease diagnosis, investments in various therapeutic modalities, creation of a collaborative research community, a unified patient community contributing essential patient data, and repositories of patient-derived specimens. The initiatives of ACD are intended to create the earliest diagnosis possible through newborn screening, to have an effective treatment, and to make disease management strategies available to all members of the CCDS community, including those diagnosed at later stages and experiencing greater effects of the diseases.

Parent Summary: This paper highlights how the Association for Creatine Deficiencies (ACD), a parent-led international advocacy group, is driving progress in the diagnosis and treatment of Cerebral Creatine Deficiency Syndromes (CCDS), which include CTD, GAMT deficiency, and AGAT deficiency. ACD goes beyond community support by actively partnering with researchers, clinicians, industry, and policymakers to accelerate diagnosis, advance therapies, and support clinical trials. Since its founding in 2012, ACD has built a collaborative research network, unified patient registry, and biospecimen repositories. Their efforts aim to achieve early diagnosis through newborn screening, develop effective treatments, and improve care for all patients, including those diagnosed later with more severe symptoms.

Link to article: https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2025.1548182/full

PubMed:  https://pubmed.ncbi.nlm.nih.gov/40078706/

Authors: Heidi Wallis, Sangeetha Iyer, Emily K. Reinhardt

Key Terms: Multiple CCDS, NBS, Clinical Study, Pediatric Patient, GAMT, AGAT, CTD